Glancy Binkow & Goldberg LLP, representing investors of NuVasive, Inc. (“NuVasive” or the “Company”) (NASDAQ:NUVA), announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of a class (the “Class”) comprising all purchasers of NuVasive securities between October 22, 2008 and July 30, 2013, inclusive (the “Class Period”).
A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW & GOLDBERG LLP. PLEASE CONTACT US TOLL-FREE AT (888) 773-9224, OR AT (212) 682-5340, OR BY EMAIL TO SHAREHOLDERS@GLANCYLAW.COM TO DISCUSS THIS MATTER OR IF YOU PURCHASED NUVASIVE SHARES PRIOR TO THE CLASS PERIOD. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.
NuVasive is engaged in the design, development and marketing of minimally disruptive surgical products and procedurally integrated solutions for the spine. The Complaint alleges that the Company issued false and/or misleading statements and failed to disclose material adverse facts about NuVasive’s business, operations and prospects. Specifically: (1) the Company improperly submitted false claims to Medicare and Medicaid in violation of federal and state laws and regulations; and (2) as a result of the foregoing, the Company’s statements were materially false and misleading at all relevant times.
On July 30, 2013, the Company disclosed that it had received a federal administrative subpoena from the Office of the Inspector General of the U.S. Department of Health and Human Services in connection with an investigation into “possible false or otherwise improper claims submitted to Medicare and Medicaid.” As a result of this news, NuVasive securities declined $3.28 per share, or over 12%, to close at $22.84 per share on July 31, 2013.If you are a member of the Class described above you may move the Court no later than October 28, 2013 to serve as lead plaintiff; however, you must meet certain legal requirements. If you wish to learn more about this action, or if you purchased NuVasive shares prior to the Class Period and have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.